Stavros Spiliopoulos1, Abdelaziz Marzoug2, Hae Ra2, Senthil Kumar Arcot Ragupathy2. 1. Department of Clinical Radiology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK;Division of Interventional Radiology, 2nd Department of Radiology, National and Kapodistrian University of Athens School of Medicine, Attikon University General Hospital, Athens, Greece. 2. Department of Clinical Radiology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
Abstract
PURPOSE: We aimed to evaluate the long-term outcomes of computed tomography-guided percutaneous cryoablation (PCA) for biopsy-confirmed renal cell carcinoma (RCC). METHODS: This was a single-center, retrospective study investigating all patients treated with PCA between January 2010 and February 2019 for RCC tumors. Primary outcome measures included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and cancer-specific survival (CSS). Secondary outcome measures included kidney function, complications, technical success, hospital stay, procedural time, and the identification of factors affecting the primary outcomes. RESULTS: Fifty-three consecutive patients with 54 lesions (T1a: 49/54; T1b: 5/54) were included. Mean tumor diameter was 28.0±8.5 mm and mean R.E.N.A.L. score was 7.2±2.0. Technical success was 100% (54/54 lesions) after two reinterventions for incomplete ablation. Mean follow-up time was 46.7±28.6 months (range, 3-122 months). Local recurrence was noted in 5 patients (9.2%). According to Kaplan-Meyer analysis, OS was 98.2%, 94.2%, 71.2%, and 58.2% at 1, 3, 5, and 8 years. One patient (1.9%) died of cancer and CSS was 95.8% at 8 years. DFS was 100.0%, 95.5%, and 88.6%, and PFS was 100%, 94.3%, and 91.0%, at 1, 2, and 5 years. Clavien-Dindo grade II complication rate was 7.8% (5/64 procedures). There were no complications classified as grade III or greater. Mean creatinine increase was 7.1±6.3 μm/L (p = 0.31). No patient advanced to dialysis during follow up. Mean procedural time was 163±45 min. Median hospital stay was 2.0 days (IQR, 1-2.5 days). Diabetes was the only independent predictor of decreased OS (hazard ratio 4.3, 95% CI 0.043-0.914; p = 0.038). CONCLUSION: PCA for stage T1a and T1b RCC provides favorable long-term oncological and renal function preservation outcomes, with acceptable complication rates.
PURPOSE: We aimed to evaluate the long-term outcomes of computed tomography-guided percutaneous cryoablation (PCA) for biopsy-confirmed renal cell carcinoma (RCC). METHODS: This was a single-center, retrospective study investigating all patients treated with PCA between January 2010 and February 2019 for RCC tumors. Primary outcome measures included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and cancer-specific survival (CSS). Secondary outcome measures included kidney function, complications, technical success, hospital stay, procedural time, and the identification of factors affecting the primary outcomes. RESULTS: Fifty-three consecutive patients with 54 lesions (T1a: 49/54; T1b: 5/54) were included. Mean tumor diameter was 28.0±8.5 mm and mean R.E.N.A.L. score was 7.2±2.0. Technical success was 100% (54/54 lesions) after two reinterventions for incomplete ablation. Mean follow-up time was 46.7±28.6 months (range, 3-122 months). Local recurrence was noted in 5 patients (9.2%). According to Kaplan-Meyer analysis, OS was 98.2%, 94.2%, 71.2%, and 58.2% at 1, 3, 5, and 8 years. One patient (1.9%) died of cancer and CSS was 95.8% at 8 years. DFS was 100.0%, 95.5%, and 88.6%, and PFS was 100%, 94.3%, and 91.0%, at 1, 2, and 5 years. Clavien-Dindo grade II complication rate was 7.8% (5/64 procedures). There were no complications classified as grade III or greater. Mean creatinine increase was 7.1±6.3 μm/L (p = 0.31). No patient advanced to dialysis during follow up. Mean procedural time was 163±45 min. Median hospital stay was 2.0 days (IQR, 1-2.5 days). Diabetes was the only independent predictor of decreased OS (hazard ratio 4.3, 95% CI 0.043-0.914; p = 0.038). CONCLUSION: PCA for stage T1a and T1b RCC provides favorable long-term oncological and renal function preservation outcomes, with acceptable complication rates.
Authors: Bimal Bhindi; Ross J Mason; Mustafa M Haddad; Stephen A Boorjian; Bradley C Leibovich; Thomas D Atwell; Adam J Weisbrod; Grant D Schmit; R Houston Thompson Journal: Eur Urol Date: 2017-09-28 Impact factor: 20.096
Authors: J Ferlay; M Colombet; I Soerjomataram; T Dyba; G Randi; M Bettio; A Gavin; O Visser; F Bray Journal: Eur J Cancer Date: 2018-08-09 Impact factor: 9.162
Authors: E Gallardo; M J Méndez-Vidal; J L Pérez-Gracia; J M Sepúlveda-Sánchez; M Campayo; I Chirivella-González; X García-Del-Muro; A González-Del-Alba; E Grande; C Suárez Journal: Clin Transl Oncol Date: 2017-11-13 Impact factor: 3.405
Authors: B M Aarts; W Prevoo; M A J Meier; A Bex; R G H Beets-Tan; E G Klompenhouwer; F M Gómez Journal: Cardiovasc Intervent Radiol Date: 2020-02-12 Impact factor: 2.740